Keyphrases
Antitumor Efficacy
82%
Patient-derived Xenograft
72%
Tumor
69%
Fibroblast Growth Factor Receptor 1 (FGFR1)
60%
Human Epidermal Growth Factor Receptor 2 (HER2)
59%
Antitumor Activity
51%
Breast Cancer Cells
50%
Mitogen-activated Protein Kinase
48%
Tumor Protein p53 (TP53)
48%
Triple-negative Breast Cancer
48%
Alternative Splicing
48%
Murine Double Minute 2 (MDM2)
48%
Paclitaxel
42%
MEK Inhibitor (MEKi)
37%
Acquired Resistance
36%
Chemotherapy
34%
Cyclin-dependent Kinase 4 (CDK4)
33%
Pathway Alteration
33%
Antibody-drug Conjugate
31%
TROP2
27%
Reverse Phase Protein Array
26%
Chemotherapy Efficacy
24%
Oncotarget
24%
Thyroid Cancer
24%
Cholangiocarcinoma
24%
Anti-human Epidermal Growth Factor Receptor 2
24%
Colorectal Cancer
24%
Co-clinical Trials
24%
PTEN Loss
24%
KPT-330
24%
Metabolic Vulnerability
24%
Breast Cancer Model
24%
SLFN11
24%
HER2-positive Cancer
24%
MDMX Inhibitor
24%
MTOR Inhibitor
24%
FGFR2 Fusion
24%
Trastuzumab Deruxtecan (T-DXd)
24%
Chemotherapy Resistance
24%
First-in-class
24%
Neratinib
24%
Hormone Receptor-positive Breast Cancer
24%
Therapeutic Efficacy
24%
Oxidative Phosphorylation (OXPHOS)
24%
Phosphoinositide 3-kinase (PI3K)
24%
Fibroblast Growth Factor Receptor Inhibitor
24%
Selinexor
24%
Bispecific
24%
ER+ Breast Cancer
24%
Adavosertib
24%
Medicine and Dentistry
Neoplasm
100%
Xenograft
72%
In Vitro
60%
Antineoplastic Activity
57%
Cancer
50%
Triple Negative Breast Cancer
48%
extracellular signal regulated kinase
48%
Combination Therapy
41%
Cancer Model
40%
Breast Cancer
36%
MEK Inhibitor
33%
Malignant Neoplasm
31%
CDK4/6 Inhibitor
29%
Antibody-Drug Conjugate
29%
Fibroblast Growth Factor Receptor 2
29%
Clinical Trial
27%
Breast Cancer Cell Line
25%
Hormone Receptor
24%
Fibroblast Growth Factor Receptor
24%
Gamma Urogastrone
24%
Neratinib
24%
Epidermal Growth Factor Receptor 2
24%
Colorectal Carcinoma
24%
Trastuzumab Deruxtecan
24%
Adavosertib
24%
Thyroid Cancer
24%
Selinexor
24%
Mammalian Target of Rapamycin Inhibitor
24%
Oxidative Phosphorylation
24%
Cholangiocarcinoma
24%
Biopsy Technique
24%
Biliary Tract Cancer
24%
Precision Oncology
24%
Paclitaxel
23%
Protein Microarray
22%
Event Free Survival
21%
Decitabine
19%
Immunohistochemistry
16%
Sacituzumab Govitecan
14%
Protein P53
14%
Cell Line
12%
MCF-7
12%
Arm
12%
Upregulation
12%
Palbociclib
12%
Treatment Group
12%
Eribulin
11%
Cell Proliferation
10%
IC50
10%
Cyclin E
10%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
93%
Breast Cancer
63%
Chemotherapy
53%
Antitumor Activity
50%
Mitogen Activated Protein Kinase
48%
Triple Negative Breast Cancer
48%
Fibroblast Growth Factor Receptor
48%
Fibroblast Growth Factor Receptor 2
48%
Combination Therapy
41%
Cancer Model
39%
Malignant Neoplasm
38%
Mitogen Activated Protein Kinase Kinase Inhibitor
33%
Clinical Trial
27%
Hormone Receptor
24%
Selinexor
24%
Gamma Urogastrone
24%
Epidermal Growth Factor Receptor 2
24%
Antibody Drug Conjugate
24%
Mammalian Target of Rapamycin Inhibitor
24%
Trastuzumab Deruxtecan
24%
Adavosertib
24%
Thyroid Cancer
24%
Neratinib
24%
Bile Duct Carcinoma
24%
Colorectal Carcinoma
24%
Decitabine
19%
Paclitaxel
17%
Event Free Survival
16%
Sacituzumab Govitecan
14%
Protein P53
14%
Palbociclib
12%
IC50
10%
Cyclin E
10%
Tumor Growth
10%
Selumetinib
9%
DNA Topoisomerase
9%
Eribulin
9%
Colon Carcinoma
8%
Biological Marker
8%
Phosphotransferase Inhibitor
8%
Fibroblast Growth Factor Receptor 1
8%
Treatment Group
8%
Pharmacodynamics
7%
Western Blot
7%
Trametinib
7%
Everolimus
7%
Cancer Growth
6%